NEWS
SSRP Institute
Oct 29, 2026

Dr. Seeds and Medivive Announce the Redox Smart Pen: A Novel Technology for Precise Peptide Administration

BREAKING NEWS

WILLOUGHBY, Ohio [October 29, 2026] — Dr. Seeds and Medivive announce the launch of the Redox Smart Pen, an innovative pre-filled autoinjector peptide delivery system designed to improve precision and consistency in physician-directed peptide protocols.

Importantly, the Redox Smart Pen was developed through a proprietary methodology focused on uniform potency, accuracy of administration, and high-quality peptides. This technology gives physicians confidence in the formulations they prescribe, while improving the patient experience.

The announcement comes as the U.S. Department of Health and Human Services (HHS) outlines an interim policy that could expand access to six compounded peptides, including BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax, through licensed 503A compounding pharmacies under specified regulatory conditions.

As the regulatory landscape surrounding peptide therapy continues to evolve, SSRP remains focused on advancing the clinical application of cellular medicine through expert professional education, physician oversight, and pharmaceutical quality.

Addressing a Critical Component of Peptide Therapy

Developed in collaboration with Medivive, the Redox Smart Pen addresses a critical consideration in peptide administration: the ability to consistently deliver high-quality peptides in the intended dose.

Traditional peptide administration can require patients to reconstitute medication, measure individual doses, and prepare injections themselves. These additional steps often introduce unintended variability, potentially affecting dosing accuracy, quality, patient adherence, and a physician’s ability to evaluate protocol effectiveness. All before even considering the legality and validity of sourcing.

The Redox Smart Pen is designed to simplify this process by providing a pre-filled delivery system that reduces the need for manual preparation and measurement and supports physician-directed protocols, without replacing individualized clinical decision-making. Crucially, it is fulfilled direct-to-patient from a licensed 503A compounding pharmacy.

Initial Focus on BPC-157, TB-500, and Semax

The initial introduction of the Redox Smart Pen will focus on three peptides: BPC-157, TB-500, and Semax. SSRP emphasizes that the clinical application of peptide therapies requires an understanding of the underlying molecular pathways, available scientific evidence, patient-specific considerations, and applicable regulatory requirements.

The Redox Smart Pen represents a new pedigree of peptide therapy through a standardized, reproducible manufacturing methodology and a delivery system for consistent products. The Redox Smart Pen is expected to become available to participating providers in November 2026.

To learn more, visit redoxpen.com.

Compounded medications are not FDA-approved. FDA does not verify their safety, effectiveness or quality before marketing.

RELATED RESOURCES

Continue exploring related topics.

VIEW ALL
Peptide Therapy Foundations: Full Curriculum
A fundamental understanding of the most clinically relevant peptides today. Foundations takes you through each covered peptide in depth: how it works, what the latest research shows, and how it’s applied in practice, all taught with one consistent clinical lens....
60 Lessons
View Course
VIDEO
Cellular Medicine Mondays
Nov 16, 2026
Ep. 114 Anti-Aging Mini Mastermind Part 4
Preview only
Journal Club – Episode 114

In Part 4 of the Anti-Aging Mini Mastermind, Dr. Seeds explores how NAD synthesis, mitochondrial function, and cellular signaling influence immune function, inflammation, and aging through the lens of cellular medicine.

Preview Only — Become a member for full access
SSRP Institute Nov 12, 2026
FDA Requires New Safety Warnings for GLP-1 Receptor Agonists Due to Potential Vision Risk
BREAKING NEWS [NOVEMBER 12, 2026] – On November 9, the U.S. Food and Drug Administration (FDA) announced new safety labeling requirements for glucagon-like peptide-1 receptor agonists (GLP-1 RAs), citing a potential increased risk of nonarteritic anterior ischemic optic neuropathy (NAION), a rare but serious condition that can cause sudden, painless vision loss, sometimes permanently. The […]
READ NEWS
VIDEO
Cellular Medicine Mondays
Nov 9, 2026
Ep. 113 - Dr. Seeds' Office Hours
Preview only
Dr. Seeds’ Office Hours – Episode 113

1. Dr. Seeds explores the clinical priorities in a 50-year-old female kidney transplant recipient with lupus, chronic steroid use, IBS, fatigue, and reported low morning glucose, focusing on metabolic function, gut health, and preserving immune tolerance. [0:47]

Preview Only — Become a member for full access
Promoitalia Nov 5, 2026
SSRP Institute Welcomes Promoitalia as New Trusted Partner
PARTNER ANNOUNCEMENT WILLOUGHBY, Ohio, [November 5, 2026] — The SSRP Institute announces that Promoitalia has joined its Trusted Partner Network following nomination and completion of the SSRP’s internal review process. Promoitalia is an Italian aesthetic medicine company that develops professional technologies, methodologies, and consumable products for regenerative aesthetics and skin health. Its work combines professional […]
READ NEWS
VIDEO
Cellular Medicine Mondays
Nov 2, 2026
Ep. 112 - Peptide Therapy Gets a Smarter Upgrade
Preview only
Dissecting Protocols – Episode 112

Peptide Therapy Gets a Smarter Upgrade

Dr. Seeds addresses the often-overlooked challenges of peptide purity, patient adherence, and administration. He also shares the journey behind the Redox Smart Pen, highlighting years of collaboration with scientists, physicians, and formulators to help raise the standard for peptide therapy and advance the future of cellular medicine.

Preview Only — Become a member for full access
VIDEO
Cellular Medicine Mondays
Oct 26, 2026
Ep. 111 - Can BPC-157 & HBOT Prevent Amputation?
Preview only
Dissecting Protocols – Episode 111

Can BPC-157 & HBOT Prevent Amputation?

Dr. Seeds explores the potential and limitations of these investigational approaches, emphasizing the importance of blood flow, patient phenotyping, and cellular function in limb salvage. (Question Link)

Preview Only — Become a member for full access
PharmaNutra Oct 22, 2026
SSRP Institute Welcomes PharmaNutra as New Trusted Partner
PARTNER ANNOUNCEMENT WILLOUGHBY, Ohio, [October 22, 2026] — The SSRP Institute announces that PharmaNutra has joined its Trusted Partner Network following nomination and completion of the SSRP’s internal review process. Founded in Italy in 2003, PharmaNutra is a pharmaceutical and nutraceutical company focused on the research, development, and production of nutritional supplements and medical devices. […]
READ NEWS
VIDEO
Cellular Medicine Mondays
Oct 19, 2026
Ep. 110 - The Macrophage Mystery: Decoding Aging
Preview only
Rabbit Holes – Episode 110

The Macrophage Mystery: Decoding Aging

In Part 3 of our Anti-Aging Mini Mastermind, Dr. Seeds explores how aging alters PGE2/EP2 signaling, influencing macrophage metabolism, immune function, and inflammation, and examines potential therapeutic implications.
Articles referenced: (2026 Article) (2021 Article)

Preview Only — Become a member for full access
VIDEO
Cellular Medicine Mondays
Oct 12, 2026
Ep. 109 - Anti-Aging Mini Mastermind Part 2
Preview only
Journal Club – Episode 109

Anti-Aging Mini Mastermind Part 2

In Part 2 of our Anti-Aging Mini Mastermind series, Dr. Seeds explores how PGE2 signaling and cellular metabolism influence inflammation, cognitive function, and aging, connecting foundational research to emerging discoveries in immunometabolism.  (2026 Article) (2021 Article)

Preview Only — Become a member for full access

Subscribe to the SSRP Community Digest

Get the latest research and developments in the field of Cellular Medicine straight to your inbox every month.

This field is for validation purposes and should be left unchanged.